KCI Obtains Injunction against Smith & Nephew in United Kingdom

UK High Court of Justice Enters Injunction Against Smith & Nephew’s NPWT Products; Injunction Stayed Pending Expedited Appeal

SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (NYSE:KCI) today announced that the High Court of Justice Chancery Division, Patents Court in the United Kingdom has entered an injunction against Smith & Nephew plc prohibiting infringement of two KCI patents relating to negative pressure wound therapy (“NPWT”). The Court stayed the injunction pending appeal, which is expected in October of this year.

“We are pleased with this decision that supports KCI’s investment in wound care innovation”

In June, the Court found that sales of SNN’s Renasys NPWT products infringe valid claims of two KCI patents. An assessment of damages will continue while the appeal is pending.

“We are pleased with this decision that supports KCI’s investment in wound care innovation,” said Mike Genau, president of KCI’s Active Healing Solutions division. “The people of KCI are proud to serve the medical community and patients in the UK, and will do all we can to help customers transition from infringing products to V.A.C.^® Therapy.”

About KCI

Kinetic Concepts, Inc. (NYSE:KCI), is a leading global medical technology company devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets. Headquartered in San Antonio, Texas, KCI's success spans more than three decades and can be traced to a history deeply rooted in innovation and a passion for significantly improving the healing and the lives of patients around the world. The company employs 6,800 people and markets its products in 20 countries. For more information about KCI, and how its products are changing the practice of medicine, visit www.KCI1.com.